Erste Asset Management Gmb H Otonomy, Inc. Transaction History

Erste Asset Management Gmb H

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 Nov 22, 2024	SELL	$1.58 - $4.06 $18,486 - $47,501	-11,700 Closed	0 $0
Q4 2019 Nov 22, 2024	BUY	$2.13 - $3.83 $24,921 - $44,811	11,700 New	11,700 $35.5 Million
Q1 2019 Nov 22, 2024	BUY	$1.8 - $2.97 $21,060 - $34,749	11,700 New	11,700 $28.5 Million

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Erste Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Erste Asset Management Gmb H with notifications on news.